Articles tagged with Hematopoietic Stem Cells
A study found a strong association between pre- and post-transplant cardio-cerebrovascular diseases, with an estimated hazard ratio of 12.50. Pre-transplant CCVD was independently associated with high non-relapse mortality and inferior survival in patients undergoing hematopoietic cell transplant.
Scientists have discovered a way to replace mutated osteoblasts with healthy ones, leading to improved collagen production and potentially paving the way for a cure for brittle bone disease. The breakthrough could be translated to other forms of OI and bone diseases in the future.
Hematopoietic stem cells use RNA from junk DNA to enhance activation after chemotherapy, leading to increased inflammatory signaling and faster blood cell production. This mechanism helps improve blood regeneration after chemotherapy.
Two studies by CU Cancer Center researchers found that chronic inflammation can serve as a key factor in the development of leukemia. Chronic inflammation reduces the fitness of normal cells, hindering their ability to reproduce and creating space for cancer-causing mutations to proliferate. The findings support the theory of adaptive ...
A study reveals that secreted cell factors, particularly TGFβ1, inhibit hematopoiesis in humans with acute myeloid leukemia. Blocking TGFβ1 could improve hematopoiesis in AML patients.
The International Osteoporosis Foundation has published a new Executive Summary outlining key guidance for managing osteoporosis in hematologic stem cell transplant recipients. The summary provides expert recommendations for monitoring, evaluation, and treatment of bone loss in HSCT patients, including a helpful management algorithm.
Researchers are developing new conditioning therapies with fewer side effects, targeting specific proteins on hematopoietic stem cells to make room for healthy ones. This could lead to more patients being able to safely undergo stem cell treatments, reducing complications and improving outcomes.
Researchers found that aged bone marrow niches restrict the function of rejuvenated hematopoietic stem cells, which can lead to leukemia. The study suggests that addressing the influence of an aged niche is crucial for sustaining the function of rejuvenated HSCs.
A study published in Science found that adult liver contains hematopoietic progenitors that can differentiate into tissue-resident lymphocytes. These findings reveal a local pathway for the development of innate lymphoid cells, providing insights into the liver's unique immune features.
Researchers found that a point mutation in the zebrafish slc20a1b gene significantly reduces the proliferation of hematopoietic stem/progenitor cells, resulting in a severe defect of hematopoietic development. The study reveals the indispensable role of slc20a1b in HSPCs, highlighting a novel regulation gene for cell cycle expansion.
A recent study reveals that long-term infection and chronic inflammation lead to a decline in immune function, particularly in older adults. The research found that Dnmt3a-loss of function HSCs exhibit increased self-renewal and reduced differentiation into immune cells, ultimately outcompeting normal HSCs.
Researchers at Children's Hospital of Philadelphia have identified genes responsible for hematopoietic stem cell regeneration via ribosome assembly. This finding enhances our understanding of the importance of proper ribosome assembly in stem cell regeneration and identifies possible targets for future therapies for ribosomopathies, ch...
Researchers at University of Tsukuba have developed a novel technique for transplanting HSCs into mouse embryos without destroying the host hematopoietic system. This breakthrough enables the study of fetal hematopoiesis and paves the way for future humanization using human HSCs.
Researchers at Massachusetts General Hospital found that atherosclerosis can accelerate the development of clonal hematopoiesis. Clonal hematopoiesis is an age-related condition where descendants of one hematopoietic stem cell dominate blood cells.
Researchers have discovered a new pathway controlling replenishment of blood cells, which could lead to novel therapeutic approaches for blood cancers. The study revealed that Tip60 plays a crucial role in maintaining hematopoietic stem cells and their DNA.
Researchers at Inselspital and the University of Bern discovered that metoclopramide inhibits the proliferation of leukemia stem cells, a key target in CML treatment. The study identifies CD93 as a specific regulator responsible for leukemia stem cell growth, paving the way for potential new therapies.
A study found that intense immunosuppression followed by hematopoietic stem cell transplants can prevent disability associated with multiple sclerosis (MS) from getting worse in up to 71% of people with relapsing-remitting MS for up to 10 years. In some cases, disability improved over time.
Researchers at Kobe University discovered that FGF23 produced by erythroblasts promotes the mobilization of hematopoietic stem cells into the peripheral blood, offering a new strategy for harvesting stem cells from bone marrow donors. This finding could help resolve issues with insufficient mobilization in around 10% of cases.
Scientists have discovered that hematopoietic stem cell function is impaired in aged mice, even when transplanted into a young bone marrow niche. The epigenome analysis reveals that DNA methylation profiles are a better indicator of aged HSC function than gene expression patterns.
Researchers have discovered a protein that can expand typically scarce blood stem cells, potentially leading to new methods for growing a large quantity of these cells inside and outside the human body. The findings could benefit patients with inherited blood disorders and certain types of blood cancers.
A new clinical trial has found that donor stem cell transplantation nearly doubles the survival rate of older patients with higher-risk myelodysplastic syndrome (MDS), aged 50-75. The study suggests that transplant should be considered for all eligible patients, ideally referred early to increase chances of finding a suitable donor.
Dana-Farber researchers will present findings related to stem cell transplant, lymphoma, leukemia, and multiple myeloma treatment, including a study on the benefit of hematopoietic cell transplantation in older patients with high-risk myelodysplastic syndrome. Another study explores the impact of clonal hematopoiesis in donors on recip...
Researchers discovered that severe infections disrupt the processes that form blood cells in mice, causing long-term damage. However, a hormone treatment and antioxidant may reduce this damage. The study found that this treatment can increase HSC function by up to tenfold.
Researchers found that RNA from repetitive elements activates RIG-I-like receptors, inducing inflammation and increasing hematopoietic stem cell numbers. The RIG-I-like receptor family plays a crucial role in regulating hematopoiesis, with different members having opposing effects on developmental hematopoiesis.
A novel computational method reveals reduced gene coordination in old cells compared to young cells across multiple organisms and cell types. The findings support Vijg's theory that a decline in gene regulation mechanisms contributes to the aging process.
A recent study has shown that graft-versus-tumor (GVT) effect associated with limited chronic graft-versus-host disease (GVHD) improves survival in high-risk myelodysplastic syndrome (MDS) patients. For those with low-risk MDS, acute and chronic GVHD did not improve overall mortality or relapse rates.
Researchers create nanoparticles that can target specific genes in bone marrow cells, showing promise for treating heart disease by reducing inflammation. The approach could also enhance stem cell yields for patients undergoing transplants.
Researchers have discovered that HSCs from early human embryos can multiply approximately 200-500 times more than those from umbilical cord blood, potentially revolutionizing blood cancer treatment. This breakthrough could lead to advances in expanding HSCs from bone marrow and cord blood, increasing the available blood supply.
Researchers found that host skin and intestinal T cells survive conditioning regimens and continue to perform their normal functions. These T cells can become activated by donor white blood cells, leading to graft-versus-host disease.
Researchers from the Center for Genomic Regulation discover Phf19 crucial for hematopoietic stem cell differentiation and balanced blood tissue. Without Phf19, mice develop disorders in blood composition compatible with early stages of leukemia.
Researchers used multiomics analysis to investigate HIV-1-infected cells in humanized mice. The study identified multiple characteristics of HIV-1-producing cells, including viral genome and transcriptomic profiles, which could provide insights for developing an HIV-1 cure.
A significant loss of intestinal goblet cells following allogeneic stem cell transplantation leads to bacterial invasion and poor prognosis. Administering IL-25 prior to transplantation can significantly reduce bacterial invasion by maintaining the mucus layer.
The study mapped the molecular characteristics of the aortic microenvironment where Hematopoietic Stem Cells (HSCs) form. Researchers identified conserved regulators, such as ADM and RAMP2, involved in HSC production in vivo.
Researchers developed a promising immunotherapy treatment for glioblastoma using CD133-targetting CAR-T therapy, which showed enhanced activity in preclinical models of human glioblastoma. The therapy was considered successful due to reduced tumor burden and improved survival rates.
Researchers identified how the enzyme MOF orchestrates the HSC fate in erythropoiesis, revealing crucial role in regulating chromatin accessibility and gene expression. This discovery could lead to new therapeutic approaches for diseases such as leukemia or anemia.
A new method uses CAR-T therapy to eliminate leukemia stem cells and blood stem cells selectively, sparing mature blood cells and other tissues. The treatment is achieved through genetic modification of immune cells, which then target and destroy only the leukemic stem cells.
Scientists successfully incorporated noncanonical amino acids into human hematopoietic stem cells, enabling the production of ncAA-containing proteins in living organisms. The modified stem cells provided a tool for studying human proteins in cell culture and living systems.
A team of international researchers led by Dr. Kunlin Jin used stem cells to boost a person's immune system and ward off COVID-19 pneumonia. The study showed that intravenous infusion of clinical-grade human mesenchymal stem cells is a safe and efficient approach for treating patients with severe cases.
Researchers at University College London have developed a new way to increase the functionality of umbilical cord blood stem cells, making them more suitable for transplantation. This breakthrough could improve treatment options for patients with blood cancers and other blood disorders.
Researchers discovered that blood stem cells can drive a rapid and efficient immune response if previously exposed to LPS, mimicking an infection. The cells store immune response circuits in their DNA using C/EBP? factor, enabling a more efficient response upon subsequent infections.
Researchers at Mount Sinai have discovered a method to increase the potency of hematopoietic stem cells, which could improve bone marrow transplants. By manipulating lysosomal activity, they enhanced the potency of these stem cells by over 90-fold.
Dr. John E. Dick has been honored with the 2020 Pezcoller-AACR Award for his discovery of leukemic stem cells and development of a hematopoietic xenograft assay. This work has provided crucial insights into leukemia progression and potential therapeutic targets.
Researchers at IU Simon Cancer Center aim to improve understanding of hematopoietic stem cell function in the bone marrow using CD166. The team is investigating CD166's role in sustaining stem cell function and identifying a molecule that allows separation of osteomacs from macrophages.
A new study may help develop personalized blood stem cells for treating leukemias and other conditions. By amplifying a regular gene, researchers can push pluripotent stem cells to produce more blood cells.
A pilot study of 25 donor-recipient pairs reveals young stem cell donors have previously undetected and potentially disease-causing mutations in their blood stem cells. These mutations, linked to post-transplant complications, are more prevalent in young donors than thought.
Dr. Margaret A. Goodell, a renowned hematopoietic stem cell researcher, has been awarded the Tobias Lecture Award by the International Society for Stem Cell Research (ISSCR). Her pioneering work on epigenetic regulators of normal hematopoietic stem cell function has greatly advanced our understanding of hematologic malignancies.
Researchers have made significant progress in generating functional hematopoietic stem cells from human pluripotent stem cells. Key findings include the role of transcription factors HOX and GATA proteins in regulating hematopoiesis, which may lead to breakthroughs in treating blood cancers and other disorders.
Researchers at Osaka University discovered that ESAM, a surface marker for hematopoietic stem cells and vascular endothelial cells, is crucial for the development of definitive hematopoiesis, especially adult-type erythropoiesis. The study found that ESAM-deficient mice had impaired hematopoiesis-supporting ability.
Hematopoietic stem cells can be purified from zebrafish kidneys using a novel purification scheme that allows researchers to collect these elusive cells. The discovery opens up new avenues for studying blood-based diseases and developing medical treatments.
A transient wave of hematopoietic stem cell production occurs in the bone marrow of late fetuses and young adults, produced from resident hemogenic endothelial cells. This discovery fills a gap in our understanding of hematopoiesis and has implications for regenerative medicine and the development of innovative stem cell therapies.
Researchers found that Viagra, combined with Plerixafor, rapidly mobilizes blood stem cells from the bone marrow into the bloodstream in mice. This approach is nearly as effective as the current standard protocol and may be a more attractive option for patients who are very ill or elderly or have undergone chemotherapy.
Researchers have demonstrated a new method to obtain donor stem cells for bone marrow transplants using a combination of Viagra and Plerixafor, which can be collected from the blood more quickly and with fewer side effects than traditional methods.
Researchers at UCLA developed a therapy that permanently boosts the body's ability to produce invariant natural killer T cells (iNKT cells), which attack human tumors. The treatment, engineered from hematopoietic stem cells, effectively suppressed tumor growth in mice with multiple myeloma and melanoma.
Researchers studied nanoparticle uptake in human stem cells and found minor effects on gene expression. The nanoparticles were encapsulated in lysosomes, ensuring their storage and preventing cell damage.
Researchers at Stanford Medicine developed an antibody treatment that enables mice to accept haploidentical hematopoietic stem cell transplants without immunosuppression. This breakthrough could transform the treatment of immune disorders and increase organ availability for transplantation.
Research reveals SIRT1's crucial role in maintaining regenerative potential of CML leukemic stem cells and promoting leukemia development. The study suggests targeting persistent leukemic stem cells with kinase-independent metabolic alterations.
Researchers have developed a more precise gene-editing technique to reduce DNA breaks and prevent cancer in stem cells. This breakthrough could improve the safety of CRISPR treatments for inherited blood disorders.
Researchers tracked and quantified blood cell production from hematopoietic stem cells, revealing that red blood cells are the default pathway for all myeloid progenitors. This finding has important implications for understanding disorders such as anemia and blood cancers.
A team of scientists has found that an analogue of vitamin B3, nicotinamide riboside, can increase the activity of hematopoietic stem cells and boost their ability to produce new blood cells. This breakthrough has significant implications for stem-cell therapy patients, particularly those undergoing chemotherapy or radiotherapy.
Harvard engineers create injectable sponge-like gel to enhance T-cell production and diversity after bone marrow transplantation, improving the immune system's ability to fight infections. The device reduces graft-versus-host disease and increases T-cell recovery rates.